Syros Pharmaceuticals, Inc. (0LC7)
London Exchange · UK · prices in USD · close of 22 Oct 2026
Key indicators
| Last close | USD 0.000 |
|---|---|
| 52-week range | 0.000 – 0.001 |
| Return, 1 month / 3 months | +0.0% / +300.0% |
| Return, 1 year / 3 years | +0.0% / −100.0% |
| Trend | Uptrend |
| RSI (14) | 96 |
| Volatility (1 year) | 772.4% |
| Worst drawdown (1 year) | -98.0% |
| Average daily value traded | 0.00M USD |
| Dividend yield | – |
Market X-Ray price-based
Five-year price chart navy: price · brown: 200-day average
About the company
Syros Pharmaceuticals is a clinical-stage biopharmaceutical company based in Cambridge, Massachusetts, that works on medicines designed to control the expression of disease-causing genes. Its research centres on small molecules that target transcription factors and related pathways, with development programmes aimed at blood cancers such as myelodysplastic syndrome and acute myeloid leukaemia. The company's customers and partners are primarily the clinical investigators, hospitals and research institutions that take part in its studies of these experimental treatments.
Syros Pharmaceuticals, Inc. trades under the code 0LC7 on the London Exchange in UK, with its price quoted in US dollars (USD). Our records, which start in 2019, show no dividend payments for it. The Market X-Ray on this page is price-based and compares it with other stocks on the same exchange; it does not measure how healthy the business is.
Summary
Syros Pharmaceuticals, Inc. (0LC7) trades on the London Exchange in UK. It last closed at USD 0.000 on 22 October 2026.
Its price-based Market X-Ray is 37 out of 100 (a weak price profile), ranking 2,772 of 3,787 stocks on this exchange. The score describes how the stock has traded: trend, momentum, risk, liquidity and dividends, each ranked against the other stocks on its own exchange. It does not measure how healthy or cheap the business is.
Over the last year the price rose 0.0% and over the last three months it rose 300.0%. Returns are price returns, dividends not included.
Fundamental measures (valuation, growth, financial health) are not shown: we do not yet hold financial statements for this market.
The five lenses in numbers each metric is ranked against the other stocks on London Exchange
| Lens and metric | Value | Score | Reading |
|---|---|---|---|
| Trend | 51 · Fair | Mixed trend against its averages. | |
| Above 200-day average | 42.6% | ||
| From 52-week high | -50.0% | ||
| Momentum | 81 · Strong | Rising faster than most stocks on this exchange. | |
| 3-month return | 300.0% | ||
| 6-month return | 100.0% | ||
| 12-month return, skipping the last month | 0.0% | ||
| Stability (higher is calmer) | 1 · Weak | Volatile, with deep drawdowns. | |
| Volatility, 1 year (lower is calmer) | 772.4% | ||
| Worst drawdown, 1 year (smaller is calmer) | -98.0% | ||
| Liquidity | 2 · Weak | Thinly traded: prices can jump and exits can be hard. | |
| Average daily value traded | 0.00M USD | ||
| Zero-volume days | 0.0% | ||
| Income | – | Pays no dividend. | |
| Dividend yield | – | ||
| Years with dividends | 0 |
Strengths
- Momentum: Rising faster than most stocks on this exchange.
Weak spots
- Stability (higher is calmer): Volatile, with deep drawdowns.
- Liquidity: Thinly traded: prices can jump and exits can be hard.
Returns
| 1 week | +0.0% |
|---|---|
| 1 month | +0.0% |
| 3 months | +300.0% |
| 6 months | +100.0% |
| 1 year | +0.0% |
| 3 years | −100.0% |
| 5 years | −100.0% |
Signals
| 50-day / 200-day average | 0.000 / 0.000 |
|---|---|
| Golden / death cross (60 days) | None |
| New 52-week high | No |
| Bullish RSI divergence | No |
| Average daily range (ATR) | 0.000 |
Technical summary
How to read this report
Every number comes from end-of-day prices and dividends. The Market X-Ray describes how the stock has traded, ranked against the other stocks on London Exchange; it does not measure how healthy or cheap the business is. The fundamental X-Ray (financial health, valuation, growth) needs financial statements, which we hold today for US stocks. See the methodology page. Educational only, not financial advice.